Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Elicio Therapeutics Inc.
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
June 17, 2026
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
June 15, 2026
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
June 1, 2026
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 25, 2026
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
May 24, 2026
Elicio Therapeutics Reports Inducement Grants
May 22, 2026
Elicio Therapeutics Reports Inducement Grants
May 17, 2026
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
May 16, 2026